Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Health Canada Approves PLEGRIDY™ (peginterferon beta-1a) for Adults with Relapsing Remitting Multiple Sclerosis
Centocor briefing document for Ustekinumab, submitted to FDA
Laquinimod suppress antigen presentation in relapsing-remitting multiple sclerosis: in-vitro high-throughput gene expression study.
The antioxidant idebenone fails to prevent or attenuate chronic experimental autoimmune encephalomyelitis in the mouse.
Control of experimental autoimmune uveoretinitis by low dose T cell vaccination.
Synthon announces successful outcome of the Phase III GATE study with its generic glatiramer acetate
Fingolimod phosphate promotes the neuroprotective effects of microglia.
Poor sleep in patients with multiple sclerosis.
Stress and the risk of multiple sclerosis.
Potassium-Retaining Diuretics: Amiloride
Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration.
Sex-related factors in multiple sclerosis susceptibility and progression.
Contactin-1 IgG4 antibodies cause paranode dismantling and conduction defects.
Early relapses, onset of progression, and late outcome in multiple sclerosis.
The neutralizing antibody GNbAC1 abrogates HERV-W envelope protein-mediated oligodendroglial maturation blockade.
The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: consensus report of the International MSCT Study Group.
Pfizer and Synthon Enter Into U.S. Commercialization Agreement for Potential Generic Treatment of Multiple Sclerosis
High-dose cyclophosphamide without stem cell rescue in 207 patients with aplastic anemia and other autoimmune diseases.
Increased axonal expression of nectin-1 in multiple sclerosis plaques.
Increased PK11195 PET binding in the cortex of patients with MS correlates with disability.
No impact of adult attachment and temperament on clinical variability in patients with clinically isolated syndrome and early multiple sclerosis.
The Effect of Three Times a Week Glatiramer Acetate on Cerebral T1 Hypointense Lesions in Relapsing-Remitting Multiple Sclerosis.
[Infections and fingolimod].
Impact of alemtuzumab treatment on the survival and function of human regulatory T cells in vitro.
Tumefactive Demyelinating Lesions in Multiple Sclerosis and Associated Disorders.

Pages